Scarica l'app Stockscreener
0.975
0.47%
0.0046
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Biovie Inc Borsa (BIVI) Ultime notizie
New to The Street’s Show #672 Airs Tonight on Fox Business Network at 10:30 PM EST - The Oklahoman
New to The Street's Show #672 Airs Tonight on Fox Business Network at 10:30 PM EST - ACCESS Newswire
BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Lubbock Avalanche-Journal
Two Sigma Investments LP Makes New Investment in BioVie Inc. (NASDAQ:BIVI) - Defense World
Millennium Management LLC Acquires Shares of 122,619 BioVie Inc. (NASDAQ:BIVI) - Defense World
Squarepoint Ops LLC Invests $28,000 in BioVie Inc. (NASDAQ:BIVI) - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in BioVie LawsuitBIVI - ACCESS Newswire
New to The Street Announces Upcoming Bloomberg Air Dates Featuring FLOKI, BioVie Pharmaceuticals, Beeline, Arrive AI, and Commercialville - The Oklahoman
Northern Trust Corp Buys Shares of 16,878 BioVie Inc. (NASDAQ:BIVI) - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIVI - ACCESS Newswire
The Law Offices of Vincent Wong Remind BioVie Investors of a Lead Plaintiff Deadline of March 19, 2024 - marketscreener.com
Investors' Lawsuit Against BioVie Moves to Evidence Review — Here's How to Recover Losses - TradingView
Transcript : BioVie Inc.Special Call - marketscreener.com
BioVie (NASDAQ:BIVI) Trading 1.9% Higher – Time to Buy? - Defense World
FY2025 EPS Estimates for BioVie Raised by Analyst - Defense World
BioVie Inc. Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - marketscreener.com
BioVie (BIVI) Begins Phase 2 Trial for Long COVID Treatment | BI - GuruFocus
BioVie (BIVI) Begins Phase 2 Trial for Long COVID Treatment | BIVI Stock News - GuruFocus
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial - GlobeNewswire
New Long COVID Treatment Hope: BioVie Launches Phase 2 Trial for 20M+ US Patients with Brain Fog - Stock Titan
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - The Manila Times
BioVie (BIVI) To Host Key Opinion Leader Event Discussing Parkin - GuruFocus
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of - GuruFocus
BioVie to host KOL event on Phase 2 study of bezisterim - TipRanks
BioVie Inc. to Host Virtual KOL Event Discussing Parkinson’s Disease and Update on Phase 2 SUNRISE-PD Trial for Bezisterim - Nasdaq
BioVie to Host Virtual KOL Event to Discuss the Phase 2 - GlobeNewswire
Biovie Inc. to Host Virtual Kol Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025 - marketscreener.com
Critical Survey: Coya Therapeutics (NASDAQ:COYA) vs. BioVie (NASDAQ:BIVI) - Defense World
BIOVIE Earnings Results: $BIVI Reports Quarterly Earnings - Nasdaq
BIOVIE INC. SEC 10-Q Report - TradingView
Lost Money on BioVie Inc.(BIVI)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
BioVie (BIVI) to Release Quarterly Earnings on Tuesday - Defense World
Investors who lost money on BioVie Inc. (BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
BioVie Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before March 19, 2024 to Discuss Your RightsBIVI - ACCESS Newswire
Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIVI - ACCESS Newswire
Investors who lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
Levi & Korsinsky Reminds BioVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024BIVI - ACCESS Newswire
Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
INVESTOR ALERT: Potential Recovery for BioVie Inc. (BIVI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Shareholders that lost money on BioVie Inc. (BIVI) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on BioVie Inc. (BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out - ACCESS Newswire
BioVie to Present Rationale and Design of Phase 2 - GlobeNewswire
BioVie (BIVI) Showcases Parkinson's Trial at Global Conference | BIVI Stock News - GuruFocus
Market Insights: BioVie Inc (BIVI)’s Notable Gain of 1.75, Closing at 1.16 - DWinneX
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):